Chimmitecan is a potent topoisomerase I inhibitor. Chimmitecan is also an active metabolite of simmitecan. Chimmitecan displays outstanding activity in vitro and in vivo. The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and oral availability, which might favorably promise its therapeutic potential in clinical settings.
Catalog Number | Size | Price | Quantity | ||
---|---|---|---|---|---|
BADC-01397 | 5 mg | $298 | Inquiry |
Chimmitecan, a potent derivative of camptothecin renowned for its efficacy in inhibiting topoisomerase I enzymes, finds diverse applications across various fields. Here are four key applications of Chimmitecan:
Cancer Therapy: In the realm of oncology, Chimmitecan emerges as a powerful weapon against different cancer types by specifically targeting topoisomerase I, a pivotal enzyme essential for DNA replication. By blocking this enzyme, Chimmitecan inflicts DNA damage in cancer cells, triggering cellular demise and shrinkage of tumors. This compound showcases remarkable effectiveness against cancers characterized by rapid cell division, such as colorectal and ovarian cancers.
Drug Development: Serving as a cornerstone in the realm of anticancer drug development, Chimmitecan undergoes structural modifications to enhance pharmacokinetics, mitigate side effects, and elevate therapeutic efficacy. These altered derivatives offer fresh avenues for treating patients resistant to current therapies, ushering in novel solutions in the fight against cancer.
Pharmacological Research: Within laboratory settings, Chimmitecan takes center stage in unraveling the intricacies of topoisomerase I inhibition and DNA damage response. By dissecting the interactions between Chimmitecan and cellular components, researchers pave the way for innovative strategies to combat drug resistance and elevate the efficacy of cancer treatments. This body of research not only enriches our understanding of DNA-interactive drugs but also propels advancements in cancer therapeutics.
Combination Therapy: Embraced as a cornerstone in combination therapies, Chimmitecan synergizes with other chemotherapeutic agents to magnify anticancer effects. Paired with compounds like paclitaxel or cisplatin, Chimmitecan potentiates the eradication of cancer cells while enabling lower dosages of each drug, thereby reducing overall toxicity. This collaborative approach not only enhances the efficacy of cancer treatments but also fosters more tolerable and efficient regimens in the battle against cancer.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.